Eli Lilly CEO Joins Other Pharma Execs, Raises Concern Over Medicare Price Negotiations Impacting Drug Development
Portfolio Pulse from Vandana Singh
Eli Lilly's CEO David Ricks raised concerns over the impact of Medicare price negotiations on drug development, specifically the Inflation Reduction Act provision. Merck filed a lawsuit against the Biden administration to weaken the Medicare price negotiation program, and Pfizer's CEO criticized the U.S. plans to negotiate drug prices.
June 14, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's CEO David Ricks is concerned about the potential impact of Medicare price negotiations on drug development.
Eli Lilly's CEO is concerned that the Inflation Reduction Act provision could harm new cures and possibilities in medicine. This negative sentiment could potentially impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Merck filed a lawsuit against the Biden administration to weaken the Medicare price negotiation program.
Merck's lawsuit against the Biden administration shows the company's opposition to the Medicare price negotiation program. This legal action could create uncertainty and negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's CEO Albert Bourla criticized the U.S. plans to negotiate drug prices for its Medicare health program.
Pfizer's CEO's criticism of the U.S. plans to negotiate drug prices for Medicare could create negative sentiment around the company and potentially impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100